Press release - 10/03/2022 Innovation Day Upper Rhine provides cross-border knowledge transfer Inspiration, innovation, networking are the name of the game on April 12, 2022, when the trinational event “Innovation Day Upper Rhine” (IDUR) takes place at the Palais Universitaire on the University of Strasbourg campus. Twelve universities in the Upper Rhine region, including the University of Freiburg and 100 partner companies of the EU funded project “Knowledge Transfer Upper Rhine” (KTUR), invite to a day of exchange and meeting.https://www.gesundheitsindustrie-bw.de/en/article/press-release/innovation-day-upper-rhine-provides-cross-border-knowledge-transfer
Press release - 02/03/2022 HPV vaccination: Numerous studies provide impressive proof of effectiveness against cervical cancer More and more data from various European countries prove: Vaccination against human papillomavirus not only prevents precancerous lesions, but also reliably protects against cervical cancer. On the occasion of the International HPV Awareness Day on March 4, Nobel laureate Harald zur Hausen hopes that many more parents will recognize this unique opportunity to protect their children from preventable cancers by vaccinating against HPV.https://www.gesundheitsindustrie-bw.de/en/article/press-release/hpv-vaccination-numerous-studies-provide-impressive-proof-effectiveness-against-cervical-cancer
Press release - 19/10/2021 Gips Schüle Research Award for three scientists from the University of Stuttgart Prof. Dr. Harald Gießen from the Institute of Physics (4) as well as Prof. Dr. Alois Herkommer and Dr. Simon Thiele from the Institute of Applied Optics at the University of Stuttgart received the Gips Schüle Research Award 2021 on October 19, 2021. The researchers were awarded the prize, which is valued at EUR 50,000.https://www.gesundheitsindustrie-bw.de/en/article/press-release/gips-schuele-research-award-three-scientists-university-stuttgart
Vaccine development - 25/05/2021 Vaccines – a beacon of hope in the fight against pandemics Having long been considered less lucrative for the big pharmaceutical companies, vaccine development is taking off in an unforeseen way in the wake of the COVID-19 pandemic. Financial support is flooding in and all kinds of vaccine development strategies are being deployed. Among the winners in the competition for effective coronavirus vaccines are vaccines based on RNA technology. The development of much-needed vaccines against many other…https://www.gesundheitsindustrie-bw.de/en/article/dossier/vaccines-beacon-hope-fight-against-pandemics
Press release - 07/01/2021 CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV Bayer has signed a collaboration and services agreement with CureVac, a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid. Under the terms of the agreement, Bayer will support the further development, supply and key territory operations of CureVac´s COVID-19 vaccine candidate CVnCoV. https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-and-bayer-join-forces-covid-19-vaccine-candidate-cvncov
Development of the genomDE genome database - 04/12/2020 Whole genome sequencing for diagnosing rare diseases Grouped together, rare diseases are by no means a rare phenomenon; however, they are rarely correctly diagnosed and rarely properly treated. In most cases, there is no effective medication available. Rare disease centres staffed by experts have been set up in many German cities to speed up the often long and painful search for the right diagnosis and treatment. Whole genome sequencing is a component of general healthcare, used to identify…https://www.gesundheitsindustrie-bw.de/en/article/news/whole-genome-sequencing-diagnosing-rare-diseases
Press release - 16/11/2020 European Commission Announces That Tomorrow It Will Authorize the Agreement with CureVac for the Supply of up to 405 Million Doses of mRNA-Based COVID-19 Vaccine Candidate, CVnCoV CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), reports the European Commission’s announcement that tomorrow it will authorize an Advanced Purchase Agreement for CureVac´s mRNA-based COVID-19 vaccine candidate, CVnCoV.https://www.gesundheitsindustrie-bw.de/en/article/press-release/european-commission-announces-tomorrow-it-will-authorize-agreement-curevac-supply-405-million-doses-mrna-based-covid-19-vaccine
Press release - 20/10/2020 EIB backs Atriva Therapeutics with €24 million for the development of a potential COVID-19 treatment The European Investment Bank (EIB) and Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, concluded a €24 million financing agreement today to facilitate the company’s development and clinical testing of a novel therapy treating severe respiratory infections with RNA viruses. RNA viruses cause diseases such as influenza, SARS and COVID-19. https://www.gesundheitsindustrie-bw.de/en/article/press-release/eib-backs-atriva-therapeutics-eur24-million-development-potential-covid-19-treatment
Press release - 15/09/2020 ELLIS inaugurates 30 research units at leading institutions across Europe At a virtual event on Tuesday, the European Laboratory for Learning and Intelligent Systems presented the broad scope of research its units will cover in the field of modern AI.https://www.gesundheitsindustrie-bw.de/en/article/press-release/ellis-offizieller-start-der-30-forschungseinheiten-fuehrenden-institutionen-ganz-europa
Stem cell therapy for regenerating intervertebral discs - 16/07/2020 Ulm’s simulator has Europe’s back Back pain is often caused by intervertebral disc disorders. Much has already been tried and is available to help patients. Despite extensive progress, there is still no surefire recipe for success. iPSpine, an EU-funded project to which researchers from Ulm are contributing interdisciplinary engineering and biomedical expertise, aims to design a novel therapy for back pain based on intervertebral disc regeneration.https://www.gesundheitsindustrie-bw.de/en/article/news/Ulms-simulator-has-europes-back
Press release - 27/04/2020 EIT Health pledges €6m funding to accelerate COVID-19 solutions EIT Health has announced over €6m of funding in the fight against COVID-19. The funding will be dedicated to 14 specially selected health innovation projects across Europe which will focus on immediate and impactful solutions that can be found to arm health services with better tools in navigating the pandemic.https://www.gesundheitsindustrie-bw.de/en/article/press-release/eit-health-pledges-eur6m-funding-accelerate-covid-19-solutions
Press release - 24/03/2020 State aid: Commission approves €300 million Luxembourg scheme to support companies affected by coronavirus outbreak The European Commission has found Luxembourg's €300 million scheme to support companies affected by the coronavirus outbreak to be in line with EU State aid rules. The scheme was approved under the State aid Temporary Framework to support the economy in the context of the COVID-19 outbreak adopted by the Commission on 19 March 2020.https://www.gesundheitsindustrie-bw.de/en/article/press-release/state-aid-commission-approves-eur300-million-luxembourg-scheme-support-companies-affected-coronavirus-outbreak
Press release - 23/03/2020 COVID-19: Commission launches European team of scientific experts to strengthen EU coordination and medical response Today, the European Commission launched an advisory panel on COVID-19 composed of epidemiologists and virologists from different Member States to formulate EU guidelines on science-based and coordinated risk management measures.https://www.gesundheitsindustrie-bw.de/en/article/press-release/covid-19-kommission-setzt-europaeisches-team-wissenschaftlicher-experten-ein-um-die-koordinierung-auf-eu-ebene-und-die-medizinis
Press release - 28/01/2019 5,5 millions for project on smart matrices for knee cartilage repair A research project in cartilage regeneration, in which the Institute of Orthopaedic Research and Biomechanics at Ulm University participates together with partners from eight european countries, was recently financed by the European Commission with 5.5 million Euro. Named RESTORE, the project aims to create 3D matrices incorporating smart nanomaterials to repair knee cartilage lesions thereby reducing or delaying the onset of osteoarthritis,…https://www.gesundheitsindustrie-bw.de/en/article/press-release/55-millions-for-project-on-smart-matrices-for-knee-cartilage-repair
Press release - 29/11/2018 Hattrick in Freiburg Three researchers at the MPI for Immunobiology and Epigenetics receive millions in funding from the European Research Council. Dominic Grün, Nicola Iovino and Ritwick Sawarkar from the Max Planck Institute of Immunobiology and Epigenetics in Freiburg will each be awareded one of the prestigious Consolidator Grants of the European Research Council. This means that 6 million euros in funding will go to fundamental research in Freiburg over the next…https://www.gesundheitsindustrie-bw.de/en/article/press-release/hattrick-in-freiburg
Article - 29/10/2018 Aminolipine: formaldehyde-free substitute for preserving biological tissues For almost 125 years, undertakers as well as physicians in the fields of anatomy and pathology have used formaldehyde to preserve biological tissue and whole cadavers. Yet, formaldehyde is highly toxic and linked to cancer. A team led by Prof. Dr. Bernhard Hirt from the Institute of Clinical Anatomy and Cell Analysis at the University Hospital in Tübingen has developed a formaldehyde-free replacement substance.https://www.gesundheitsindustrie-bw.de/en/article/news/aminolipine-formaldehyde-free-substitute-for-preserving-biological-tissues
Article - 15/09/2017 Zika virus infections and their consequences Infections caused by mosquito-borne Zika viruses during pregnancy can lead to severe brain defects in babies. The European Union has provided funding of around ten million euros for an international research programme on Zika virus infections in which the University Hospital of Heidelberg plays a key role. https://www.gesundheitsindustrie-bw.de/en/article/news/zika-virus-infections-and-their-consequences
Article - 26/04/2017 Chaperones disassemble Parkinson’s disease-specific amyloid fibrils Amyloid fibrils consisting of clumped α-synuclein protein are characteristic of Parkinson's disease. Chaperones, which ensure the correct folding of newly synthesised polypeptides, can inhibit α-synuclein aggregation and, as a consequence, prevent fibrils from forming. Researchers from Heidelberg have shown that a specific combination of human molecular chaperones is able to disassemble fibrils and transform them into non-toxic α-synuclein…https://www.gesundheitsindustrie-bw.de/en/article/news/chaperones-disassemble-parkinsons-disease-specific-amyloid-fibrils
Press release - 05/04/2017 New EU rules on medical devices to enhance patient safety and modernise public health The Commission welcomes the adoption of its proposal for two Regulations on medical devices which establish a modernised and more robust EU legislative framework to ensure better protection of public health and patient safety.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-eu-rules-on-medical-devices-to-enhance-patient-safety-and-modernise-public-health
Prenatal diagnosis - 23/03/2017 Microdroplets for safe and rapid prenatal diagnoses Although the methods used to carry out amniocentesis are quite sophisticated, there is still a 0.5 percent risk of miscarriage following the intervention. Therefore, an EU-funded project called AngeLab is developing a rapid test that only requires a blood sample of the mother rather than amniotic fluid. The test yields information on the genetic health of the foetus within only a few hours. As part of the project, researchers from the…https://www.gesundheitsindustrie-bw.de/en/article/news/microdroplets-for-safe-and-rapid-prenatal-diagnoses
Article - 22/02/2017 MammaScreen – blood test for early detection of breast cancer The MammaScreen team from the University of Heidelberg Women’s Hospital has developed a blood test for diagnosing breast cancer. This new test can detect breast cancer at a very early stage. It works on women of all ages with tumours of any type and size. https://www.gesundheitsindustrie-bw.de/en/article/news/mammascreen-blood-test-for-early-detection-of-breast-cancer
High-tech - 20/10/2016 Industry 4.0 in the medical technology and pharmaceutical industry sectors The digitalisation of industry affects the entire value chain. From individual products to digitising workflows in companies and connecting companies with clients and service providers via the Internet of Things – Industry 4.0 makes completely new manufacturing processes possible and requires new and specific business models. https://www.gesundheitsindustrie-bw.de/en/article/dossier/industry-40-in-the-medical-technology-and-pharmaceutical-industry-sectors
Press release - 12/02/2016 ERC Consolidator Grants: € 585 million for 302 top researchers in Europe The European Research Council (ERC) has announced today the 302 winners of its 2015 Consolidator Grant competition. These excellent mid-career scientists are awarded a total of €585 million, as part of the European Union Research and Innovation programme Horizon 2020. With grants worth up to €2 million each, they will be able to consolidate their research teams and to develop their innovative ideas.https://www.gesundheitsindustrie-bw.de/en/article/press-release/erc-consolidator-grants-585-million-for-302-top-researchers-in-europe
Article - 02/02/2016 EU consortium to speed up innovations in the healthcare sector EIT Health is a large-scale European project launched in December 2014 that aims to help people in Europe to live a healthier life and stay active as they grow older. The consortium brings together 140 leading companies and institutions from 14 European countries and has a total budget of two billion euros. It is one of the largest networks worldwide in the healthcare sector.https://www.gesundheitsindustrie-bw.de/en/article/news/eu-consortium-to-speed-up-innovations-in-the-healthcare-sector
Article - 04/08/2014 Europe’s first gene therapy Scientists from the National Center for Tumour Diseases (NCT) have shown that adeno-associated viruses (AAV) do not pose a cancer risk. This conclusion is based on the analysis of several million patient cells treated with AAV and the finding that the viruses do not integrate into the patient genome. AAV is the first-ever gene therapy for clinical use in the Western world. AAV vectors could also potentially be used as prototypes for the treatment…https://www.gesundheitsindustrie-bw.de/en/article/news/europe-s-first-gene-therapy